Cargando…
Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
Autores principales: | Lamba, Jatinder K., Meshinchi, Soheil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561291/ https://www.ncbi.nlm.nih.gov/pubmed/34092060 http://dx.doi.org/10.3324/haematol.2021.279043 |
Ejemplares similares
-
Gemtuzumab Ozogamicin: Back Again
por: Selby, Chris, et al.
Publicado: (2019) -
Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
por: Mamolo, Carla, et al.
Publicado: (2020) -
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial
por: Rafiee, Roya, et al.
Publicado: (2019) -
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
por: Teich, Katrin, et al.
Publicado: (2021) -
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020)